An allogeneic hematopoietic stem cell transplantation that triggers graft-vs.-host-disease (GVHD) involves T cells that do not come from the patient's bloodstream, but rather from the local progenitor ...
As a hematologist and physician-scientist who specializes in bone marrow transplantation, Dr. Albert Yeh describes the “holy grail” of transplantation biology that has yet to be answered: “how do you ...
A recent study by a team led by Professor Shin Kaneko successfully induced regulatory T cell (Treg)-like cells from iPS cell-derived conventional helper T cells (Tconvs) and demonstrated their ability ...
Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...
It’s possible to manage graft-versus-host disease (GVHD) with appropriate treatments. Your individualized treatment plan will depend on your symptoms, their severity, and the disease’s response to ...
The FDA has approved axatilimab-csfr (Niktimvo) for treating adults and children with chronic graft-versus-host disease who have progressed on at least 2 prior treatments. The FDA approved ...
The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...
SEATTLE — With increasing survival rates after allogeneic hematopoietic stem cell transplantation (HSCT) in children, dermatologists may be seeing more skin conditions associated with HSCT, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results